Immunoglobulin (Ig) G is the dominant secondary immune antibody and it has the longest half-life of the five groups (IgA, IgD, IgE, IgG, and IgM) because of recycling by neonatal Fc receptors (FcRn). Since they lack FcRn immunity, there are also some downsides of the ultra-short half-life of non-IgG antibodies that make their use largely inadmissible: fast clearance from the blood, rapid shedding, poor persistence on the target (e.g., tumors). At present, Creative Biolabs has launched antibody half-life extension service for non-IgG antibodies to optimize stability and performance.
Our Service
Creative Biolabs has developed a state-of-the-art antibody half-life extension service designed to overcome the inherent stability challenges of non-IgG antibodies. Through innovative engineering approaches, we enhance pharmacokinetics and extend circulation time, ultimately maximizing therapeutic impact.
Key Strategies
Modifying the glycosylation of non-IgG antibodies enhances their pharmacokinetic and pharmacodynamic properties, enabling them to be retained in vivo longer. It selectively regulates glycosylation to increase stability and lengthen the half-life of antibodies.
Our C-terminal fusions fuse human albumin or FcRn-binding sequences to non-IgG antibodies, resolving the lack of FcRn-binding sequences and prolonging the half-life of the antibody.
The construction of hybrid antibodies combines non-IgG structures with IgG-like features, leveraging the stability and FcRn binding characteristics of IgG antibodies while retaining non-IgG-specific benefits.
Through albumin-binding modifications, non-IgG antibodies gain extended in vivo exposure, increasing their therapeutic window and efficacy in a variety of applications.
Highlights
-
Extended Stability and Efficacy
Increasing the half-life of non-IgG antibodies extends their biological lifespan, enabling therapeutic agents to function longer. This cuts down on the amount of dose that can be administered, resulting in greater compliance and overall better patient results. -
Enhanced Pharmacokinetics
By leveraging advanced glycoengineering and albumin-binding strategies, our half-life extension techniques improve blood circulation time, target retention, and delivery to specific tissues. This results in more efficient and sustained antibody activity, making it suitable for both preclinical and clinical research. -
Reduced Treatment Costs
With fewer administrations required due to extended half-life, treatment cycles become less frequent, lowering the associated healthcare costs and minimizing the burden on patients and healthcare providers. -
Minimized Immunogenicity
Our engineering strategies include modifications to non-IgG antibodies that not only extend half-life but also reduce the risk of immunogenic responses. By using biocompatible components and tailored modifications, we support a safer therapeutic profile, essential for clinical applications. -
Comprehensive Customization Options
Each project is designed with flexibility to meet specific therapeutic goals, species requirements, and application needs. Our customizable approach allows us to optimize the antibody half-life extension process to the unique requirements of each client's research or clinical objectives. -
Dedicated Technical Support and Consultation
Creative Biolabs provides ongoing technical support, ensuring seamless project execution and addressing any specific challenges encountered during the half-life extension process. Our experts guide clients through each step, delivering tailored solutions and addressing any adjustments needed to meet project specifications. -
Innovative Approach for Non-IgG Antibodies
Our focus on non-IgG antibodies, such as IgM, IgA, and IgE, demonstrates our commitment to expanding beyond traditional IgG engineering, offering innovative strategies that meet the unique challenges and therapeutic potential of these antibody classes. -
Scalability for Future Development
Our service is equipped to scale from initial research stages to full clinical production, providing consistency in quality and performance across different phases. This scalability supports a streamlined transition from laboratory research to therapeutic applications.
Background
Half-life is the average duration of time elapsed after antibody molecules are formed, which is typically defined as the period of time it takes to flush out half of the known content of immunoglobulin from an animal's body. In clinical applications, a very short serum half-life opens up new uses and dosages of medications. As therapeutic antibodies continue to grow on the global market, a great deal of attention has been given to optimizing the engineering, safety, and efficacy of therapeutic antibodies, and stability is among the top priorities frequently discussed during the preclinical development process. The benefit of extending the half-life of therapeutic antibodies ranges from therapeutic improvement to improved patient compliance, which ultimately means fewer treatment cycles and lower costs. With these reassuring advantages in mind, designers will often optimize the stability of the antibodies by appropriately lengthening the half-life once they have determined which therapeutic antibodies they want.
Fig.1 Different strategies to extend the half-life of therapeutic protein.1
FAQs
Q1: Why do we prolong the half-life of non-IgG antibodies?
A: Increasing the half-life means that non-IgG antibodies stay in action longer in the body, decreasing the need for multiple doses, decreasing the cost of treatment, improving patient compliance, and possibly increasing therapeutic effectiveness across a variety of fields.
Q2: What techniques does Creative Biolabs use to extend the half-life of non-IgG antibodies?
A: The technologies Creative Biolabs uses are glycoengineering, C-terminal albumin/FcRn-binding motif fusion, hybrid antibodies, and improved albumin-binding capacity. These techniques are tailored to maximize stability, retention, and therapeutic efficiency.
Q3: What is glycoengineering and how does it help in extending antibody half-life?
A: Glycoengineering is a process for adjusting the glycosylation patterns of antibodies to optimize their pharmacokinetic and pharmacodynamic actions. This strategy maintains antibody reactivity in the body so that non-IgG antibodies continue to work for longer.
Q4: How do Creative Biolabs ensure minimal immunogenicity in modified antibodies?
A: We utilize biocompatible components and tailored modifications in our engineering strategies to reduce the risk of immunogenic responses while maintaining the desired half-life extension.
Q5: What types of non-IgG antibodies can be modified using this service?
A: Our service can modify various non-IgG antibodies including IgM, IgA, and IgE, with specialized strategies for each antibody class's unique characteristics.
Q6: Can your service be customized for specific applications?
A: Yes, our service offers complete customization to meet specific therapeutic goals, species requirements, and application needs, providing flexible optimization processes tailored to each project's unique demands.
Q7: What technical support do you provide during the development process?
A: We deliver comprehensive technical support throughout the entire development process, including expert consultation, project guidance, process optimization, and continuous support to ensure project success.
Q8: How do you verify the success of a half-life extension?
A: We implement comprehensive testing protocols to measure serum half-life, stability profiles, target binding efficiency, and pharmacokinetic properties, ensuring the modified antibodies meet the desired specifications.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody - Creative Biolabs
Quotation and Ordering
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Reference
- AlQahtani, Alanod D., et al. "Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment." Biomedicine & Pharmacotherapy 113 (2019): 108750. Distributed under the Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
